Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06113471 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

A Phase 3 study of NonSegmental Vitiligo, sponsored by Incyte Corporation.

Active
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT06113471 is a Phase 3 study of NonSegmental Vitiligo that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 450 participants, above the 282-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06113471, a Phase 3 study of NonSegmental Vitiligo, is active but no longer recruiting, sponsored by Incyte Corporation.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Conditions Studied

NonSegmental Vitiligo

Interventions

  • DRUG Placebo
  • DRUG Povorcitinib

Study Locations (20)

California

  • First Oc Dermatology Research Inc - Fountain Valley
  • Center For Dermatology Clinical Research, Inc - Fremont
  • Marvel Clinical Research Llc - Huntington Beach
  • Vitiligo & Pigmentation Institute of Southern California - Los Angeles
  • Dermatology Research Associates - Los Angeles
  • Clinical Trials Research Institute - Thousand Oaks

Florida

  • Skin Care Research, Llc - Boca Raton
  • Total Vein and Skin Llc - Boynton Beach
  • Driven Research Llc - Coral Gables
  • Florida Academic Centers Research and Education Llc - Coral Gables
  • Pediatric Skin Research Llc - Coral Gables
  • Metabolic Research Institute Inc - West Palm Beach

Alabama

  • University of Alabama At Birmingham Hospital-Whitaker Clinic - Birmingham
  • C2 Research Center, Llc - Montgomery

Georgia

  • Dermatology and Surgery Specialists of North Atlanta - Marietta
  • Advanced Medical Research Pc - Sandy Springs

Illinois

  • Dundee Dermatology - West Dundee

Indiana

  • Indiana University School of Medicine Iusm Indianapolis - Indianapolis

Louisiana

  • Delricht Research - Baton Rouge

Maryland

  • Callender Dermatology and Cosmetic Center - Glenn Dale

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2023-11-27
Est. Completion 2027-03-16
Phase Phase 3

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06113471

The ClinicalTrials.gov registry entry for NCT06113471 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 282-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (60% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with NonSegmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06113471 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06113471 about?

NCT06113471 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)". This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

What is the current status of trial NCT06113471?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2023-11-27. Estimated completion is 2027-03-16.

What conditions does trial NCT06113471 study?

This clinical trial studies the following conditions: NonSegmental Vitiligo.

What interventions are being tested in trial NCT06113471?

The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).

Who is sponsoring clinical trial NCT06113471?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06113471 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for NonSegmental Vitiligo

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

NonSegmental Vitiligo

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.